AR029619A1 - Vacuna - Google Patents

Vacuna

Info

Publication number
AR029619A1
AR029619A1 ARP000100821A ARP000100821A AR029619A1 AR 029619 A1 AR029619 A1 AR 029619A1 AR P000100821 A ARP000100821 A AR P000100821A AR P000100821 A ARP000100821 A AR P000100821A AR 029619 A1 AR029619 A1 AR 029619A1
Authority
AR
Argentina
Prior art keywords
medicine
refers
ige
new
regions
Prior art date
Application number
ARP000100821A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Biolog
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904408.3A external-priority patent/GB9904408D0/en
Priority claimed from GBGB9917144.9A external-priority patent/GB9917144D0/en
Priority claimed from GBGB9918604.1A external-priority patent/GB9918604D0/en
Priority claimed from GBGB9918601.7A external-priority patent/GB9918601D0/en
Priority claimed from GBGB9918599.3A external-priority patent/GB9918599D0/en
Priority claimed from GBGB9918598.5A external-priority patent/GB9918598D0/en
Priority claimed from GBGB9918606.6A external-priority patent/GB9918606D0/en
Priority claimed from GBGB9925618.2A external-priority patent/GB9925618D0/en
Application filed by Smithkline Beecham Biolog, Peptide Therapeutics Ltd filed Critical Smithkline Beecham Biolog
Publication of AR029619A1 publication Critical patent/AR029619A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP000100821A 1999-02-25 2000-02-25 Vacuna AR029619A1 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9904408.3A GB9904408D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9917144.9A GB9917144D0 (en) 1999-07-21 1999-07-21 Vaccine
GBGB9918604.1A GB9918604D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918601.7A GB9918601D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918599.3A GB9918599D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918598.5A GB9918598D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918606.6A GB9918606D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9925618.2A GB9925618D0 (en) 1999-10-29 1999-10-29 Vaccine

Publications (1)

Publication Number Publication Date
AR029619A1 true AR029619A1 (es) 2003-07-10

Family

ID=27571340

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100821A AR029619A1 (es) 1999-02-25 2000-02-25 Vacuna

Country Status (18)

Country Link
EP (1) EP1155038A1 (ko)
JP (1) JP2002537403A (ko)
KR (1) KR20020007314A (ko)
CN (1) CN1520423A (ko)
AR (1) AR029619A1 (ko)
AU (1) AU3281100A (ko)
CA (1) CA2363641A1 (ko)
CO (1) CO5231139A1 (ko)
CZ (1) CZ20013081A3 (ko)
HK (1) HK1043134A1 (ko)
HU (1) HUP0105490A3 (ko)
IL (1) IL145025A0 (ko)
MX (1) MXPA01008612A (ko)
NO (1) NO20014131L (ko)
NZ (1) NZ513680A (ko)
PL (1) PL350992A1 (ko)
TR (1) TR200102493T2 (ko)
WO (1) WO2000050461A1 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045745A2 (en) * 1999-12-21 2001-06-28 Acambis Research Limited A reversible linkage technology for controlled conjugation
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CN1668637B (zh) 2002-07-17 2010-05-26 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
PL375598A1 (en) 2002-07-18 2005-12-12 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
PL217409B1 (pl) 2002-07-19 2014-07-31 Cytos Biotechnology Ag Kompozycja, kompozycja farmaceutyczna i kompozycje szczepionki zawierające układ antygenowy amyloidu beta 1-6 oraz sposób ich wytwarzania i zastosowanie
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
CA2517839A1 (en) 2003-03-26 2004-10-07 Martin F. Bachmann Melan-a peptide analogue-virus-like-particle conjugates
CN102702359A (zh) * 2004-02-02 2012-10-03 泰勒公司 新的IgE表位的鉴别
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
AU2006297304B2 (en) 2005-09-29 2012-05-17 Medimmune, Llc Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
RU2451523C2 (ru) 2005-12-14 2012-05-27 Цитос Биотехнологи Аг Упакованные иммуностимулирующей нуклеиновой кислотой частицы, предназначенные для лечения гиперчувствительности
WO2007144150A1 (en) 2006-06-12 2007-12-21 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
EP2376108B1 (en) 2008-12-09 2017-02-22 Pfizer Vaccines LLC IgE CH3 PEPTIDE VACCINE
CA2800774A1 (en) * 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 ＩｇＥペプチドワクチン
AU2019247321A1 (en) * 2018-04-06 2020-10-22 Slsbio Co., Ltd. Novel epitope of immunoglobulin E, antibody binding thereto, and kit for analyzing immunoglobulin E in sample containing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02229200A (ja) * 1989-02-28 1990-09-11 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有するペプチド
DE69232944T2 (de) * 1991-08-14 2003-12-24 Genentech, Inc. Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
WO1997031948A1 (en) * 1996-03-01 1997-09-04 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate

Also Published As

Publication number Publication date
IL145025A0 (en) 2002-06-30
EP1155038A1 (en) 2001-11-21
MXPA01008612A (es) 2003-06-24
HK1043134A1 (zh) 2002-09-06
NZ513680A (en) 2001-09-28
HUP0105490A2 (hu) 2002-04-29
PL350992A1 (en) 2003-02-24
AU3281100A (en) 2000-09-14
CN1520423A (zh) 2004-08-11
CA2363641A1 (en) 2000-08-31
WO2000050461A1 (en) 2000-08-31
NO20014131D0 (no) 2001-08-24
HUP0105490A3 (en) 2002-05-28
JP2002537403A (ja) 2002-11-05
TR200102493T2 (tr) 2002-02-21
CO5231139A1 (es) 2002-12-27
CZ20013081A3 (cs) 2002-02-13
KR20020007314A (ko) 2002-01-26
NO20014131L (no) 2001-10-02

Similar Documents

Publication Publication Date Title
AR029619A1 (es) Vacuna
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
Harrison et al. Research strategies to improve snakebite treatment: Challenges and progress
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
AR066987A1 (es) Anticuerpo monoclonal contra proteina beta-amiloide
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
CR10244A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
ATE414534T1 (de) Immunotherapeutische methoden und systeme
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
EA200101064A1 (ru) Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
EA201991526A1 (ru) Конъюгаты антитела и лекарственного средства для разрушения гемопоэтических стволовых клеток
EA202191244A1 (ru) Новые цитостатические конъюгаты с лигандами интегрина
ES2376564B1 (es) Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
Sibaud et al. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
AR045765A1 (es) Moleculas de union a cd45 y uso terapeutico
RU2011130522A (ru) Моноклональное антитело против hcv в качестве лекарственного средства для терапевтического лечения и профилактики инфекций hcv
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
Lee et al. Bee venom-associated Th1/Th2 immunoglobulin class switching results in immune tolerance of NZB/W F1 murine lupus nephritis
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
BR112023000455A2 (pt) Tratamento de doença inflamatória que usa anticorpos de fator antitecidual
AR029336A1 (es) Peptidos utiles para preparar medicamentos para el tratamiento, prevencion o mejoramiento de estados alergicos, inmunogenos,epitopos y mimotopos, vacunas, ligandos, composiciones farmaceuticas; uso de los peptidos ,de los ligandos en la preparacion de medicamentos; proceso para preparar vacunas y pr
RU2015147913A (ru) Антитело против рецептора эпидермального фактора роста

Legal Events

Date Code Title Description
FA Abandonment or withdrawal